Amylyx Pharmaceuticals, Inc. Common Stock
AMLXAmylyx Pharmaceuticals, Inc. is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company is known for its innovative approach combining neuroscience and clinical research to address conditions such as amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders. Amylyx's leading product candidate, AMX0035, is designed to potentially slow disease progression and improve patient quality of life.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| April 2, 2018 | $0.42 | 2018-03-28 | 2018-03-29 |
| January 2, 2018 | $0.36 | 2017-12-28 | 2017-12-29 |
| October 2, 2017 | $0.24 | 2017-09-28 | 2017-09-29 |
Dividends Summary
- Consistent Payer: Amylyx Pharmaceuticals, Inc. Common Stock has rewarded shareholders with 3 dividend payments over the past 1 years.
- Total Returned Value: Investors who held AMLX shares during this period received a total of $1.02 per share in dividend income.
- Latest Payout: The most recent dividend of $0.42/share was paid 2853 days ago, on April 2, 2018.
- Yield & Schedule: AMLX currently pays dividends quarterly with an annual yield of 6.26%.
- Dividend Growth: Since 2017, the dividend payout has grown by 74.3%, from $0.24 to $0.42.
Company News
Antisense oligonucleotide (ASO) therapeutics are emerging as a promising treatment approach for rare genetic and neuromuscular disorders, with over 70 pharmaceutical companies actively developing 90+ pipeline therapeutics targeting specific genetic mechanisms.
Law firm investigating potential claims against Amylyx Pharmaceuticals regarding allegedly misleading statements about Relyvrio drug launch and patient demand during November 2022 to November 2023 period.
Law firm investigating potential claims against Amylyx Pharmaceuticals regarding allegedly misleading statements about Relyvrio drug launch and patient demand during November 2022-2023.
Amylyx Pharmaceuticals' stock rose over 10% this week after the company reported positive results from a phase 2 clinical trial of its drug AMX0035 for the rare genetic disorder Wolfram Syndrome. The treatment was well-tolerated and showed sustained improvement in pancreatic function, leading the company to plan discussions with the FDA about adv...
Amylyx Pharma (NASDAQ:AMLX) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent So...
